Correlation Between Enanta Pharmaceuticals and Xeris Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Enanta Pharmaceuticals and Xeris Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enanta Pharmaceuticals and Xeris Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enanta Pharmaceuticals and Xeris Pharmaceuticals, you can compare the effects of market volatilities on Enanta Pharmaceuticals and Xeris Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enanta Pharmaceuticals with a short position of Xeris Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enanta Pharmaceuticals and Xeris Pharmaceuticals.

Diversification Opportunities for Enanta Pharmaceuticals and Xeris Pharmaceuticals

-0.53
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Enanta and Xeris is -0.53. Overlapping area represents the amount of risk that can be diversified away by holding Enanta Pharmaceuticals and Xeris Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Xeris Pharmaceuticals and Enanta Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enanta Pharmaceuticals are associated (or correlated) with Xeris Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Xeris Pharmaceuticals has no effect on the direction of Enanta Pharmaceuticals i.e., Enanta Pharmaceuticals and Xeris Pharmaceuticals go up and down completely randomly.

Pair Corralation between Enanta Pharmaceuticals and Xeris Pharmaceuticals

Given the investment horizon of 90 days Enanta Pharmaceuticals is expected to under-perform the Xeris Pharmaceuticals. In addition to that, Enanta Pharmaceuticals is 1.46 times more volatile than Xeris Pharmaceuticals. It trades about -0.21 of its total potential returns per unit of risk. Xeris Pharmaceuticals is currently generating about 0.13 per unit of volatility. If you would invest  288.00  in Xeris Pharmaceuticals on September 13, 2024 and sell it today you would earn a total of  63.00  from holding Xeris Pharmaceuticals or generate 21.88% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Enanta Pharmaceuticals  vs.  Xeris Pharmaceuticals

 Performance 
       Timeline  
Enanta Pharmaceuticals 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enanta Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Xeris Pharmaceuticals 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Xeris Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Xeris Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Enanta Pharmaceuticals and Xeris Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Enanta Pharmaceuticals and Xeris Pharmaceuticals

The main advantage of trading using opposite Enanta Pharmaceuticals and Xeris Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enanta Pharmaceuticals position performs unexpectedly, Xeris Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Xeris Pharmaceuticals will offset losses from the drop in Xeris Pharmaceuticals' long position.
The idea behind Enanta Pharmaceuticals and Xeris Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Other Complementary Tools

Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk